Doug Doerfler is the former CEO of MaxCyte, Inc., a biotechnology company he led from March 2017 until December 2023. With an MBA from the Wharton School, University of Pennsylvania, he has a solid background in the industry. Under his...

Doug Doerfler is the former CEO of MaxCyte, Inc., a biotechnology company he led from March 2017 until December 2023. With an MBA from the Wharton School, University of Pennsylvania, he has a solid background in the industry. Under his leadership, MaxCyte focused on cell therapy and biotechnology solutions that have significantly impacted healthcare. Doerfler's strategy emphasized cash compensation and performance-based bonuses. In 2023, his total compensation hit about $3.14 million, driven by a base salary and performance metrics including revenue and product development targets. Interestingly, he also made major stock option grants totaling 400,000 shares in 2023, highlighting his commitment to the company's growth and shareholder value. His reported holdings once peaked at over $8.61 million in value in late 2021, showing that he has skin in the game. Apart from that, he structured his retirement with 18 months of salary as a transition agreement, aiming for a smooth handover to his successor. Doug's tenure included pivotal phases for MaxCyte, making him a significant figure in the biotech arena.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other MaxCyte CEOs

M

Doug Doerfler

Ex-CEO of MaxCyte

Education

MBA from the Wharton School, University of Pennsylvania.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1963 - 62 years ago

CEO of MaxCyte for

6 years 9 months (Mar 2017 - Dec 2023)

Previous Experience

CEO of MaxCyte, Inc. since March 2017. Previously held various leadership roles in biotechnology and life sciences companies.

Rivals

Competitors/colleagues of Doug Doerfler

Holdings

See how much did Doug Doerfler make over time.

Doug Doerfler's stock holdings saw significant value fluctuations during his time at MaxCyte. His peak financial power came in November 2021 when his holdings were valued around $8.61 million. However, over the following years, the value decreased with steady monthly...

Doug Doerfler's stock holdings saw significant value fluctuations during his time at MaxCyte. His peak financial power came in November 2021 when his holdings were valued around $8.61 million. However, over the following years, the value decreased with steady monthly fluctuations. By 2023, his reported holdings showed a drop to about $4.07 million in January 2023. This decline reflects the natural ups and downs of the stock market, demonstrating that even CEOs face investment challenges. His strategy involving stock option grants also indicates a long-term commitment to boosting company performance, aligning his interests directly with those of shareholders.

Total Stock Sold

$5.58M

MXCT

$5.58M

660,000 MXCT shares

What if they kept their stock?

If Doug Doerfler didn't sell their stock, today they would have:
Extra MXCT660,000 shares worth $11.22M.
This is 100.93% and $5.64M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Doug Doerfler.

MXCT

$633.45K

MXCT at $5.09/share

Dec 4, 2023

Sale

MXCT

$127.75K

MXCT at $5.00/share

Nov 29, 2023

Sale

MXCT

$150.70K

MXCT at $5.02/share

Jul 10, 2023

Sale

MXCT

$220.79K

MXCT at $5.04/share

Jun 13, 2023

Sale

MXCT

$81.07K

MXCT at $5.02/share

May 3, 2023

Sale

MXCT

$75.00K

MXCT at $5.00/share

Apr 10, 2023

Sale

MXCT

$174.64K

MXCT at $5.02/share

Apr 5, 2023

Sale

MXCT

$51.02K

MXCT at $5.01/share

Mar 31, 2023

Sale

MXCT

$171.90K

MXCT at $5.73/share

Feb 1, 2023

Sale

MXCT

$152.40K

MXCT at $5.08/share

Jan 3, 2023

Sale

Compensation History

See how much did Doug Doerfler make over time.

In 2023, Doug Doerfler earned a total compensation package worth approximately $3.14 million. This included a base salary of $641,300 and a performance-based annual bonus of $572,100, which was tied to the company's financial success, particularly in generating revenue and improving EBITDA. Interestingly, despite his focus on cash compensation, he received stock options in March 2023 amounting to 400,000 shares that vest over time. His compensation structure emphasizes aligning executives' incentives with the broader goals of MaxCyte's growth. Overall, his package reflects both his contributions to the company and the high expectations set for leadership in the biotech industry.

Year

2023

Total Compensation

$2.34M

Salary

$641.30K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on cash compensation and performance-based bonuses.

Bonus

$572.10K

Board Justification

Annual bonus for 2023 based on performance metrics including revenue and EBITDA, paid in the first quarter of 2024.

Other

$1.12M

Board Justification

Includes severance payments, health insurance benefits, and legal fees related to retirement and transition agreement.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation and performance bonuses.

Performance Metrics

Performance metrics included revenue, EBITDA, and product development targets.

Other MaxCyte CEOs

Here are other CEOs of MaxCyte

Maher Masoud

CEO of MaxCyte

January 2024 - Present